Fibrosis‑4 (FIB‑4) index and mortality in COVID‑19 patients admitted to the emergency department: a new interesting predictive index for patients with COVID-19 disease?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. FIB-4, APRI, and ALRI as Predictors of COVID-19 Outcomes: Insights from a Large-Scale Study.Diagnostics (Basel, Switzerland) · 2025
   Article
2. Time‑dependent ROC curve analysis to determine the predictive capacity of seven clinical scales for mortality in patients with COVID‑19: Study of a hospital cohort with very high mortality.Biomedical reports · 2024
   Article
3. The FIB-4 scores in the emergency department to predict the outcomes of COVID-19 patients in taiwan.Heliyon · 2024
   Article
4. Clinical characteristics and risk factors associated with diverse manifestations of COVID-19 in patients aged 85 years and older.Frontiers in public health · 2024
   Article

Corrections and comments

• Comment on
  Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency department.2022

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as